A Pilot Study of 5-Azacytidine and Oral Sodium Phenylbutyrate in Severe Thalassemia
Individuals with homozygous beta-thalassemia are either severely anemic or dependent on
blood transfusion to sustain life. Deficient synthesis of the beta chain leads to
imbalanced chain synthesis with an excess of alpha globin. This alpha globin precipitates,
causing ineffective erythropoiesis and shortened red cell survival. In patients with
homozygous beta-thalassemia, enhanced gamma globin synthesis could partially compensate for
the deficient synthesis of beta globin rendering chain synthesis more balanced and reducing
the relative excess of alpha chains. The purpose of this protocol is to test the hypothesis
that induction therapy with 5-azacytidine, followed by maintenance treatment with oral
phenylbutyrate will enhance gamma globin synthesis, increase red cell production and
partially or substantially correct the anemia in patients with homozygous beta-thalassemia.
Interventional
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
United States: Federal Government
000166
NCT00005934
June 2000
June 2003
Name | Location |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Bethesda, Maryland 20892 |